AMSTERDAM, July 23, 2014 /PRNewswire/ --
QUOSA now offers customers with CCC licenses the full benefits of integration at no extra cost, significantly lowering barriers to copyright compliance
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that QUOSA, its literature management solution, and Copyright Clearance Center (CCC) have extended their relationship to support greater compliance in the use of full text articles within corporate or institutional environments. Using CCC's rights advisory API, QUOSA customers who are also CCC licensees can view their license rights directly from QUOSA at no extra cost to the user.
QUOSA users can instantly check the usage rights of documents within the QUOSA library by accessing the CCC database via a single user interface, helping them to quickly determine how they may use a document; for example, checking if they can share an article with colleagues. This significantly increases the efficiency of content management workflows, helping users manage large libraries of information and ensure compliance requirements are met. QUOSA and CCC first partnered in 2009; the expansion of this relationship will now deliver the same seamless functionality at no extra cost.
"Ensuring compliance is a mammoth task for both researchers and Information Managers alike. Users need to be sure they are using documents in a compliant manner and Information Managers must avoid the significant financial penalties that can result from failed compliance," said Daan de Jong, Director Product Development for Elsevier. "This latest enhancement to QUOSA supports our drive to make QUOSA the 'one stop shop' for literature management. Integrating QUOSA with per-article rights data at no extra cost takes away the uncertainty surrounding compliance that is experienced by pharmacovigilance and medical affairs personnel when accessing scientific literature."
QUOSA is a centralized repository of scientific literature that enables life sciences institutions to meet regulatory reporting requirements, address medical inquiries and maintain current awareness in relation to topics or authors. It is used by a broad array of groups such as pharmacovigilance and medical affairs personnel in pharma, biotech and medical device companies. CCC is a leading global rights-licensing technology organization, providing solutions that simplify compliance for content users, promoting the work of creators and supporting the principles of copyright.
QUOSA is part of Elsevier's Life Science Solutions, a portfolio of domain-specific, decision support tools which span the discovery and development workflow and work together to support key research outcomes. The portfolio includes Embase, Pathway Studio, PharmaPendium, ScienceDirect, Scopus, TargetInsights, Reaxys and Reaxys Medicinal Chemistry.
For more information on QUOSA please visit: http://www.elsevier.com/online-tools/quosa
About Copyright Clearance Center
Copyright Clearance Center (CCC), a leading global rights-licensing technology organization, provides solutions that simplify compliance for content users, promotes the work of creators and supports the principles of copyright. A rights broker for the world's most sought-after journals, books, blogs, movies and more, CCC makes it easy for businesses and academic institutions to use, share and store copyrighted material while compensating content creators for their works. With its international subsidiary, RightsDirect, CCC serves more than 35,000 customers and 12,000 publishers around the world.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Director, Strategic Communications